Rosetta Genomics (ROSG) – Press Releases
-
Rosetta Announces That Completion of Genoptix Transaction Uncertain
-
Nasdaq Hearing Panel Determined to Delist Shares of Rosetta Genomics from Nasdaq Stock Market Effective May 22, 2018
-
Rosetta Receives an Additional Delisting Notice from Nasdaq
-
Rosetta Genomics Announces Shareholder Approval of Merger with Genoptix
-
Shareholder Meeting Adjourned to April 26, 2018
-
Rosetta Announces Resignation of CEO
-
Action Required Before Potential Bankruptcy
-
Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix
-
Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide
-
Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix Merger
-
Genoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics
-
Genoptix Enters into New Agreements to Acquire Rosetta Genomics for $9 Million in Cash
-
Rosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with Genoptix
-
Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix
-
Genoptix to Acquire Rosetta Genomics for $10 Million in Cash
-
Rosetta Genomics Receives NASDAQ Notification
-
Rosetta Genomics Provides Update on RosettaGX Reveal(TM)
-
Rosetta Genomics Expands Patent Protection for Thyroid microRNA Biomarkers with U.S. Patent Allowance
-
Rosetta Genomics Receives NASDAQ Notification
-
Favorable Data from Independent Study Comparing RosettaGX Reveal(TM) versus Afirma(R) to Accurately Classify Indeterminate Thyroid Nodules Were Presented at the 87th Annual Meeting of the American Thy
-
Rosetta Genomics Expands Patent Estate for Thyroid Cancer Detection microRNA Biomarkers with U.S. Patent Allowance
-
RosettaGX Reveal to be Highlighted in Poster Presentations at the 87th Annual Meeting of the American Thyroid Association
-
Rosetta Genomics and MediNcrease Health Plans Announce Provider Agreement Expanding Access to RosettaGX(TM) Reveal and Other Testing Services
-
Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results
-
Rosetta Genomics Announces $2 Million Private Placement
-
Rosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin Prognosis
-
Rosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in Japan
-
Rosetta Genomics to Reduce Operating and Other Expenses
-
Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice
-
Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay
-
Rosetta Genomics Announces 1-for-12 Reverse Stock Split
-
Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures
-
Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth Quarter and Year
-
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs
-
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering
-
Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients
-
Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology
-
RosettaGX Reveal™ Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology
-
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
-
Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its Novel microRNA Platform Technology
-
Rosetta Genomics Enters Distribution Agreement for RosettaGX Reveal™ in Israel with Rhenium
-
Rosetta Genomics Reports 2016 Second Quarter Financial Results
-
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016
-
Rosetta Genomics to Present at Upcoming September Conferences
-
Data Validating the Utility of RosettaGX Reveal™ with Liquid-based Cytology Samples will be Presented at the 86th Annual Meeting of the American Thyroid Association
-
RosettaGX Reveal™ Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep® Samples
-
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer
-
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera Health
-
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services
-
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment
Back to ROSG Stock Lookup
